key: cord-1029513-svlxgh6v
authors: Cioccarelli, Chiara; Sánchez-Rodríguez, Ricardo; Angioni, Roberta; Venegas, Francisca C.; Bertoldi, Nicole; Munari, Fabio; Cattelan, Annamaria; Molon, Barbara; Viola, Antonella
title: IL1β Promotes TMPRSS2 Expression and SARS-CoV-2 Cell Entry Through the p38 MAPK-GATA2 Axis
date: 2021-12-07
journal: Front Immunol
DOI: 10.3389/fimmu.2021.781352
sha: 0db171e170f21c0f20e78fad62921a092b97a9fd
doc_id: 1029513
cord_uid: svlxgh6v

After the outburst of the SARS-CoV-2 pandemic, a worldwide research effort has led to the uncovering of many aspects of the COVID-19, among which we can count the outstanding role played by inflammatory cytokine milieu in the disease progression. Despite that, molecular mechanisms that regulate SARS-CoV-2 pathogenesis are still almost unidentified. In this study, we investigated whether the pro-inflammatory milieu of the host affects the susceptibility of SARS-CoV-2 infection by modulating ACE2 and TMPRSS2 expression. Our results indicated that the host inflammatory milieu favors SARS-CoV-2 infection by directly increasing TMPRSS2 expression. We unveiled the molecular mechanism that regulates this process and that can be therapeutically advantageously targeted.

At more than one year after the Coronavirus disease 19 (COVID-19) has been declared a global pandemic, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is still threatening the healthcare systems around the world. The critical and severe forms of COVID-19 are associated with pneumonia and Acute Respiratory Distress Syndrome (ARDS), conditions that are triggered by deregulated immunity and uncontrolled inflammation. In particular, the inflammatory cytokine milieu of the patient plays a crucial role in COVID-19 progression. Indeed, specific cytokines have been linked to worse severity, longer hospitalization time, or to patient's age (1) . Accordingly, multiple diseases such as diabetes and obesity, as well as aging, that are characterized by chronic inflammation and elevated levels of pro-inflammatory cytokines, represent high risk factors for developing a severe illness after SARS-CoV-2 infection (2) . Among the cytokines that have been associated to COVID-19 severity, several reports identified higher levels of IL1b in severe and critical patients compared with mild and moderate ones (3) . Actually, SARS-CoV-2 infection is known to trigger the NLRP3 inflammasome activation in various cell types and the activation of this pathway, that leads to a strong increase in IL1b release, might exacerbate ARDS and systemic inflammation (4) . SARS-CoV-2 entry into the target cells involves the binding of the viral spike protein (S) to the host Angiotensin I Converting Enzyme 2 (ACE2) receptor and its proteolytical activation by proteases. Following the binding of the S1 subunit to ACE2 through its receptor-binding domains (RBD), the host transmembrane protease/serine subfamily 2 (TMPRSS2) cleaves the S protein to facilitate membranes fusion (5) . The expression levels and the co-expression of ACE2 and TMPRSS2 seem to be key factors in determining the susceptibility of target organs to SARS-CoV-2 infection (6) . Recently, it has been proved that ACE2 expression can be regulated in response to interferon alpha and gamma signaling (7) , linking the immune response to the modulation of the cell receptors that mediate SARS-CoV-2 entry. TMPRSS2 is expressed in several tissues including lungs, gastrointestinal tract and kidney. Notably, the TMPRSS2 gene is upregulated in response to androgenic hormones (8) , suggesting that the expression of this protease might be involved in the observed higher severity of COVID-19 in men compared to women.

In this study, we investigated whether the pro-inflammatory milieu of the host affects TMPRSS2 and ACE2 expression in SARS-CoV-2 target cells. To this aim, the A549 human lung cell line was exposed to various concentrations of IL1b, IL6, and TNFa inflammatory cytokines and the expression level of TMPRSS2 and ACE2 mRNA was evaluated. Interestingly, we found that IL1b and TNFa stimulation enhanced the transcription of TMPRSS2 ( Figure 1A and Supplementary Figure 1A ). On the other side, TNFa and IL1b treatment did not affect ACE2 expression that was rather increased by IL6 (Supplementary Figures 1B, C) . The effect of IL1b over TMPRSS2 and ACE2 expression was also confirmed in primary immortalized human alveolar epithelial cells (TT1) ( Figure 1B and Supplementary Figure 1D ).

In addition to TMPRSS2, other proteases, such as ADAM17 and FURIN, have been reported to promote SARS-CoV-2 infection (9) but none of them appeared to be transcriptionally regulated by pro-inflammatory cytokine stimulation in the A549 cells (Supplementary Figure 2) .

In line with other reports (4), our data confirmed that COVID-19 patients showed an increased level of circulating IL1b ( Figure 1C ) compared to healthy subjects. Notably, IL1b concentration was significantly higher in severe and critical patients compared with mild and moderate ones ( Figure 1D ). Therefore, we focused our analysis on IL1b-induced transcriptional regulation of TMPRSS2 expression. We first validated the induction of TMPRSS2 expression by IL1b stimulation at the protein level by performing immunofluorescence and western blot analyses on both A549 ( Figure 3 ). Furthermore, we evaluated whether IL1b stimulation can modulate SARS-CoV-2 endosome and replication relatedgenes such as IFITM2 (10) and RNF20 (11) . No transcriptional changes were observed for these genes upon IL1b stimulation in lung cells (Supplementary Figure 4) .

Previous studies showed that TMPRSS2 expression is controlled by the master regulator transcription factor GATA2 through its binding to the -13 kb DNA enhancer region of the gene (-13 kb upstream the promotor) (8) . Furthermore, GATA2 activation has been reported to be mediated by its phosphorylation via p38 MAPK pathway (12) . GATA2 is also involved in the transcriptional regulation of several proinflammatory cytokines, including IL1B and CXCL2 (12) . In addition, a positive feedback between IL1b signaling and GATA2 activation has been previously described in Acute Myeloid Leukemia (12) . Thus, we speculated that IL1b may induce TMPRSS2 expression through the p38 MAPK-GATA2 axis. To validate our hypothesis, we first analyzed the effect of IL1b stimulation in A549 and TT1 cells in the presence or absence of specific inhibitors that selectively block p38 MAPK and GATA2 activity. Remarkably, we observed that TMPRSS2 transcription was significantly decreased by the treatment with p38 MAPK (Birb796) or GATA2 (K7174) inhibitors in IL1bstimulated A549 and TT1 cells (Figures 1K, L and Supplementary Figure 5A ). ACE2 transcription was not affected by the inhibitors (Supplementary Figure 5B) .

In order to confirm the role of GATA2 on the IL1b-induced transcriptional regulation of TMPRSS2, GATA2 chromatin immunoprecipitation was performed. Our results showed that the chromatin enrichment in the TMPRSS2 -13 kb enhancer region was increased upon IL1b stimulation ( Figure 1M) . Importantly, the p38 MAPK and GATA2 inhibitors, that blocked TMPRSS2 overexpression induced by IL1b, were also able to inhibit the GATA2 binding to the enhancer region ( Figure 1M ). Moreover, GATA2 transcription was not affected by pro-inflammatory cytokine exposure (Supplementary Figure 6) , suggesting that the outlined effect relies on GATA2 activity rather than on a modulation of its expression level. To further corroborate the role of GATA2 on TMPRSS2 transcription upon IL1b stimulation, we performed GATA2 silencing in A549 cells. Our results confirmed that the downregulation of GATA2 expression blocked the enhancement of TMPRSS2 transcription in response to IL1b exposure. ( Figure 1N and Supplementary Figures 7A-C) .

Finally, we evaluated whether the IL1b-induced TMPRSS2 overexpression could increase cell susceptibility to SARS-CoV-2 infection. A549 and TT1 cells were exposed to the nonreplicative heat-inactivated SARS-CoV-2 virus, in presence or absence of IL1b and of the selected inhibitors. We observed that IL1b exposure increased the virus entry (Figures 1O-R and Supplementary Figures 7D, E) , which was significantly inhibited by the pharmacological block of the p38 MAPK-GATA2 axis. IL1b has been reported to promote the expression of interferon response genes in epithelial and myeloid cells (13) . We found that IL1b stimulation promoted the overexpression of IRF1 (Supplementary Figures 8A, B ) and its target (14) storm syndrome in COVID-19 patients (15, 16) . Future high throughput studies should be performed to better understand the interconnection between IL1b and innate immune response in SARS-CoV-2 infection. Collectively, our results indicated that the host inflammatory milieu might favor SARS-CoV-2 infection by increasing TMPRSS2 expression. In addition, we identified the molecular pathway that regulates this process that can be therapeutically targeted. Our findings unveiled a novel pathogenetic mechanism that associates the pro-inflammatory cytokine IL1b with an increased susceptibility to SARS-CoV-2 infection. Importantly, co-downregulation of IL1B and TMPRSS2 upon azithromycin treatment was recently described in basal nasal epithelial cells, further suggesting a link between inflammation and protease expression in SARS-CoV-2 infection (17) . Thus, targeting IL1b may not only reduce high inflammatory responses in severe COVID-19 patients, but also limit the viral entry in lung epithelial cells.

Peripheral Blood (PB) was collected in EDTA tubes from enrolled controls and 44 COVID-19 patients that were admitted to the Infectious and Tropical Disease Unit of the University Hospital of Padua. Plasma was obtained after peripheral blood mononuclear cells (PBMC) isolation by density-gradient sedimentation using Ficoll-Paque PLUS (GE Healthcare, Germany) according to the manufacturer's protocol. Then, plasma was carefully removed from the 2/3 of the top layer using a sterile serological pipette until the mononuclear cell interphase and stored at −80°C until the analysis. The median age of the patients was 59.3 years (98-25). All patients were clinically diagnosed with COVID-19 (at least one positive laboratory PCR test for SARS-CoV-2 infection). All patients were classified into mild, moderate, severe, and critical cases based on results from chest imaging, clinical examination, and symptoms (WHO guidelines). The study was performed according to the ethical guidelines of the Declaration of Helsinki (7th revision). The study was approved by the Ethics Committee and the general authorization issued by the Data Protection Authority. Cod CESC n. 4933/AO/20.

IL1b level was analyzed in the plasma from 4 controls and 44 patients by Luminex assay (Millipore, Billerica, USA). The diluted standard and quality control were used according to the manufacturer's instructions. The plate was read on Luminex 200 ™ . Analysis was performed using xPONENT 3.1 software.

Human A549 cell line was donated from ECSIN lab, Padua. The cells were maintained in DMEM high glucose medium supplemented with 1% Na-pyruvate, 1% L-glutamine, 10% Gibco FBS, 1% Penicillin-Streptomycin at 37°C under 5% CO2, while human alveolar epithelial cell line (TT1) were maintained as Montagner et al. reported (18) . Cells were stimulated with recombinant human IL1b, IL6 or TNFa (PeproTech) at the concentration of 1, 15 or 50 ng/mL either in combination or not with the inhibitors BIRB 796 (100 nM) or K-7174 (10 µM) (Selleck Chemicals). Vehicle treated and non-stimulated cells were used as a control condition. The treatment medium was composed of DMEM high glucose supplemented with Penicillin-Streptomycin and 2% FBS Gibco. RNA extraction was performed after 4 hours of treatment, whereas protein extraction was performed after 24 hours of treatment.

Cells were transfected with GATA2 Stealth siRNA or scramble Silencer Select Negative Control (Thermo Fisher Scientific), according to the manufacturer's protocol. Briefly, cells were plated 24h hours before transfection in a growth medium without antibiotics. Stealth siRNA -Lipofectamin2000 (Invitrogen) complexes were prepared according to the manufacturer's instructions. Both siRNA and scramble were used at the concentration of 75 pmol. 24 hours after transfection cells were stimulated with recombinant human IL1b as previously described. RNA extraction was performed after 4 hours of treatment.

Total RNA was extracted for RT-qPCR analysis from unstimulated and stimulated cells with TRIzol reagent (Thermo Fisher Scientific) following manufacturer instructions. 500 ng of RNA were retrotranscribed using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer instructions. cDNA was diluted 1:10 and amplified with specific primers for the human genes TMPRSS2, ACE2, GATA2, FURIN, ADAM17 and GAPDH ( Table 1) using Power SYBR Green Master Mix (Thermo Fisher Scientific) on a QuantStudio ™ 5 Real-Time PCR System, 384-well (Applied Biosystems). The analysis of the obtained results was performed by the DDCt method.

For the evaluation of cell susceptibility to SARS-CoV-2 infection, concerning the RNA extraction, we followed the protocol by Vogels et al. (19) . We then performed reverse transcription as described above and RT-qPCR as described by WHO (20).

Chromatin immunoprecipitation was performed with MAGnify ™ Chromatin Immunoprecipitation System (Thermo Fisher Scientific) according to the manufacturer's protocol. Briefly, cells were plated and after 24 hours they were starved for 1 hour; then they were stimulated or not with recombinant IL1b (50 ng/mL) and either treated or not with the indicated inhibitors in presence of IL1b (50 ng/mL). After 4 hours of treatment, the DNA-transcription factor crosslink was performed with 1% formaldehyde (Sigma Aldrich) in PBS for 15 min at RT in soft shaking; the reaction was stopped with 

Protein lysates from A549 or TT1 cells were prepared using a lysis buffer (10 mM Tris-HCl pH 9, 4% SDS, 1 mM DTT). 5 µg of total protein extracts were loaded for western blot in Bolt ™ 4-12% Bis-Tris Plus gels (Thermo Fisher Scientific) and blotted onto a PVDF membrane (Bio-Rad). Membranes were blocked with 3% bovine serum albumin (Sigma Aldrich) for 1 hour and then incubated with the primary antibodies a-TMPRSS2 antibody (EPR3862, Abcam) or a-GRP75 (D-9, Santa Cruz Biotechnology) at 4°C. After that, membranes were incubated with the secondary antibody goat a-rabbit IgG (H + L)-HRP Conjugate (Bio-Rad) for 1 hour. Chemiluminescence was detected with iBright 1500 (Invitrogen). Images were analyzed with ImageJ software (Fiji) and the protein was quantified and normalized on the housekeeping protein (GRP75) and on the non-stimulated condition.

For TMPRSS2 protein immunofluorescence, A549 and TT1 cells were either stimulated or not with IL1b for 24 hours. By contrast, for the evaluation of cell susceptibility to SARS-CoV-2 infection, cells were either stimulated or not with IL1b and the selected inhibitors for 8 hours as previously described. The infection was then performed, using Heat-inactivated SARS-CoV-2 (VR-1986HK, ATCC) at 4 TCID50/mL. 72 hours after the infection, cells were fixed with PFA 4% (Sigma) in PBS, blocked with blocking solution (PBS, 1% BSA, 0,02% NP40) and incubated with SARS-CoV-2 spike antibody (polyclonal, GeneTex) followed by anti-rabbit Alexa Fluor 488 antibody (polyclonal, Invitrogen). Nuclei were counterstained with Hoechst 33342 (Invitrogen) and actin was stained with Phalloidin TexasRed (Invitrogen). Fluorescence images were acquired using the Zeiss LSM 800 confocal laser scanning microscope. The fluorescent signal per cell was quantified using ImageJ software (Fiji) and the corrected total cell fluorescence (CTCF) was calculated. TMPRSS2 staining in A549 and TT1 cells was performed by using H-4 (Santa Cruz Biotechnology) antibody according to the indicated protocol. 3D reconstruction was performed using ZEN 3.2 Blue edition software (Carl Zeiss).

Data are reported as the mean ± SEM of at least 3 independent experiments. Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software). Comparisons between two groups were performed by the nonparametric Mann-Whitney U test or Kruskal-Wallis test for multiple comparisons with Dunn's post hoc test *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by the Ethics Committee and the general authorization issued by the Data Protection Authority. Cod CESC n. 4933/AO/ 20. The patients/participants provided their written informed consent to participate in this study. Mann-Whitney U test. **P < 0.01, ****P < 0.0001.

Age-Severity Matched Cytokine Profiling Reveals Specific Signatures in Covid-19 Patients

Comorbidities and the Risk of Severe or Fatal Outcomes Associated With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Characterization of the Inflammatory Response to Severe COVID-19 Illness

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Entry Factors are Highly Expressed in Nasal Epithelial Cells Together With Innate Immune Genes

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues

Androgen Regulation of the TMPRSS2 Gene and the Effect of a SNP in an Cioccarelli et al. Role of IL1b in SARS-CoV-2 Receptors Expression Frontiers in Immunology | www

ACE2/ADAM17/ TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19

IFITM Proteins Promote SARS-CoV-2 Infection and are Targets for Virus Inhibition In Vitro

Protease Cleavage of RNF20 Facilitates Coronavirus Replication via Stabilization of SREBP1

GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells

Interleukin-1b Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING

IRF1 Up-Regulates Isg15 Gene Expression in dsRNA Stimulation or CSFV Infection by Targeting Nucleotides -487 to -325 in the 5' Flanking Region

Altered ISGylation Drives Aberrant Macrophage-Dependent Immune Responses During SARS-CoV-2 Infection

ISG15 Secretion Exacerbates Inflammation in SARS-CoV-2 Infection

Azithromycin Downregulates Gene Expression of IL-1b and Pathways Involving TMPRSS2 and TMPRSS11D Required by SARS-CoV-2

Crosstalk With Lung Epithelial Cells Regulates Sfrp2-Mediated Latency in Breast Cancer Dissemination

SalivaDirect: A Simplified and Flexible Platform to Enhance SARS-CoV-2 Testing Capacity

Identification of Interleukin1b as an Amplifier of Interferon Alpha-Induced Antiviral Responses

Interferon-Induced Transmembrane Protein 3 Inhibits Hantaan Virus Infection, and Its Single Nucleotide Polymorphism Rs12252 Influences the Severity of Hemorrhagic Fever With Renal Syndrome

Genetic Framework for GATA Factor Function in Vascular Biology

RNF20 Is Critical for Snail-Mediated E-Cadherin Repression in Human Breast Cancer

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest